Evidence map›Paper›PMID 34460997›Full record

ArticleJournal of diabetes investigation2022

Maternally inherited diabetes and deafness coexists with lipoprotein lipase gene mutation-associated severe hyperlipidemia that was resistant to fenofibrate and atorvastatin, but sensitive to bezafibrate: A case report.

Xiaojuan Zhang, Yongyong Chen, Nanwei Tong, Qing Shao, Yueyang Zhou, Tong Mu, Xiaoling Yang, Yuwei Zhang

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of diabetes investigation, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Xiaojuan ZhangDepartment of Endocrinology and Metabolism, West China Hospital of Sichuan University, Chengdu, China.
Yongyong ChenDepartment of Endocrinology and Metabolism, West China Hospital of Sichuan University, Chengdu, China.
Nanwei TongDepartment of Endocrinology and Metabolism, West China Hospital of Sichuan University, Chengdu, China.ORCID https://orcid.org/0000-0002-5395-3660
Qing ShaoDepartment of Endocrinology and Metabolism, West China Hospital of Sichuan University, Chengdu, China.
Yueyang ZhouDepartment of Endocrinology and Metabolism, West China Hospital of Sichuan University, Chengdu, China.
Tong MuDepartment of Endocrinology and Metabolism, West China Hospital of Sichuan University, Chengdu, China.
Xiaoling YangDepartment of Endocrinology and Metabolism, West China Hospital of Sichuan University, Chengdu, China.
Yuwei ZhangDepartment of Endocrinology and Metabolism, West China Hospital of Sichuan University, Chengdu, China.ORCID https://orcid.org/0000-0003-2281-5000
Sichuan University · CN

Funding

Data Center of Management Science, National Natural Science Foundation of China - Peking University 82070660Innovation Spark Project of Sichuan University 2018SCUH0084Sichuan Regional Innovation Cooperation Project 20QYCX0100
6 · The paper itself

Abstract

Maternally inherited diabetes and deafness is a rare genetic disease mainly caused by a point mutation in mitochondrial deoxyribonucleic acid. Lipoprotein lipase gene mutations are associated with familial dyslipidemias, which are difficult to manage. We reported for the first time a case that had both maternally inherited diabetes and severe hyperlipidemia caused by lipoprotein lipase gene mutation (C.347(exon3)G>C) that was resistant to fenofibrate and atorvastatin. We were able to manage the patient's hyperlipidemia with bezafibrate, and her diabetes was well controlled with insulin. In conclusion, genetic testing is helpful in identifying rare and interesting cases when clinicians suspect inheritable diseases. Additionally, when one fibrate drug is ineffective in treating hyperlipidemia, it might be worthwhile trying another fibrate.

Indexed as

Diabetes Mellitus, Type 2FenofibrateHyperlipidemiasAtorvastatinBezafibrateDeafnessFemaleHumansLipoprotein LipaseMitochondrial DiseasesMutationAtorvastatinBezafibrateFenofibrateLipoprotein LipaseLPL protein, humanHypertriglyceridemiaLipoprotein lipaseMaternally inherited diabetes and deafness

Identifiers

PMID34460997
PMCPMC8847153
OpenAlexW3197265271

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.